Deal Library / Pharma BD Deal Intelligence

Respiratory Deals

The Pharma Closeout tracks 25 deals, $59.4B in disclosed deal value, 18 with a post-close Outcome Score for Respiratory.

Median Critic Score: 79  ·  Median Outcome Score: 60

Best outcome: Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. (85)  ·  Weakest outcome: AstraZeneca PLC / Pieris Pharmaceuticals, Inc. (16)

All 25 deals

• Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. — 2017 · $250M · Worked — the deal delivered on its rationale.
• Madison Dearborn Partners / Ikaria Inc. — 2013 · $1.6B · Worked — the deal delivered on its rationale.
• AstraZeneca PLC / Amgen Inc. — 2020 · $2.3B · Worked — the deal delivered on its rationale.
• GlaxoSmithKline plc / Theravance, Inc. — 2012 · $213M · Worked — the deal delivered on its rationale.
• Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) — 2018 · $2.3B · Worked — the deal delivered on its rationale.
• GSK plc / Jiangsu Hengrui Pharmaceuticals Co. Ltd. — 2025 · $12.0B · Largely worked — most objectives met.
• Zymeworks Inc. / Theravance Biopharma, Inc. — 2026 · $929M · Largely worked — most objectives met.
• Mylan Inc. / Theravance Biopharma, Inc. (TD-4208 program) — 2015 · $265M · Largely worked — most objectives met.
• AstraZeneca PLC / Pearl Therapeutics Inc. — 2013 · $1.1B · Largely worked — most objectives met.
• GSK plc / Aiolos Bio — 2024 · $1.0B · Largely worked — most objectives met.
• Roche Holding AG / InterMune Inc. — 2014 · $8.3B · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / Takeda Pharmaceutical Company Limited (core respiratory business) — 2015 · $575M · Underwhelmed — fell short of the thesis.
• Sanofi SA / Translate Bio Inc. — 2021 · $3.2B · Underwhelmed — fell short of the thesis.
• AstraZeneca PLC / Almirall S.A. (respiratory franchise) — 2014 · $2.1B · Underwhelmed — fell short of the thesis.
• Tyco International Ltd. / Mallinckrodt Inc. — 2000 · $4.2B · Did not work — the deal failed to deliver.
• Merck & Co., Inc. / Afferent Pharmaceuticals, Inc. — 2016 · $1.2B · Did not work — the deal failed to deliver.
• Cephalon, Inc. / Ception Therapeutics — 2010 · $250M · Did not work — the deal failed to deliver.
• AstraZeneca PLC / Pieris Pharmaceuticals, Inc. — 2017 · $2.2B · Did not work — the deal failed to deliver.
• Merck & Co. Inc. / Verona Pharma plc — 2025 · $10.0B
• GSK plc / Bellus Health Inc. — 2023 · $2.0B
• AbbVie Inc. / DJS Antibodies Ltd. — 2022 · $255M
• Pfizer Inc. / ReViral Ltd. — 2022 · $525M
• GlaxoSmithKline plc / Vir Biotechnology Inc. — 2021 · $345M
• Boehringer Ingelheim GmbH / Bridge Biotherapeutics, Inc. — 2019 · $1.2B
• Elan Corporation plc / Theravance Inc. (royalty interest) — 2013 · $1.0B

← Deal Library  ·  Interactive search  ·  How we score deals